Because CEACAM1 is gradually lost in hepatocytes and endothelial cells in MASH patients as fibrosis progresses, the data promote CEACAM1 induction as a potential therapeutic strategy. This evidence concerns the gene CEACAM1 and metabolic dysfunction-associated steatohepatitis.